125 related articles for article (PubMed ID: 17285116)
1. Enhancing effect of new biological response modifier sulfoethylated (1-->3)-beta-D-glucan on antitumor activity of cyclophosphamide in the treatment of experimental murine leukoses.
Khalikova TA; Korolenko TA; Zhanaeva SY; Kaledin VI; Kogan G
Exp Oncol; 2006 Dec; 28(4):308-13. PubMed ID: 17285116
[TBL] [Abstract][Full Text] [Related]
2. [Effect of biological response modifier sulfoethylated (1 --> 3)-beta-D-glycan on the experimental leukemia in mice].
Khalikova TA; Korolenko TA
Eksp Klin Farmakol; 2006; 69(5):39-43. PubMed ID: 17153965
[TBL] [Abstract][Full Text] [Related]
3. Regulation of activity of cathepsins B, L, and D in murine lymphosarcoma model at a combined treatment with cyclophosphamide and yeast polysaccharide.
Khalikova TA; Zhanaeva SY; Korolenko TA; Kaledin VI; Kogan G
Cancer Lett; 2005 Jun; 223(1):77-83. PubMed ID: 15890239
[TBL] [Abstract][Full Text] [Related]
4. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
Borden EC; Sidky YA; Hatcher JF; Bryan GT
Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
[TBL] [Abstract][Full Text] [Related]
6. [The lysosomal cathepsins B, L and D in development of murine experimental leukemias].
Khalikova TA; Korolenko TA; Il'nitskaia SI
Biomed Khim; 2009; 55(5):621-34. PubMed ID: 20017393
[TBL] [Abstract][Full Text] [Related]
7. Forphenicinol enhances the antitumor effects of cyclophosphamide in a model of squamous cell carcinoma.
Murphy KT; Wardak A; Beckett MA; Lopez CA; Mehta N; Kimchi E; Salloum RM; Jaskowiak NT; Posner MC; Ohno T; Kufe DW; Weichselbaum RR; Mauceri HJ
Cancer Chemother Pharmacol; 2005 Sep; 56(3):317-21. PubMed ID: 15887016
[TBL] [Abstract][Full Text] [Related]
8. Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs.
Li LH; DeKoning TF; Wallace TL
Cancer Res; 1987 Nov; 47(22):5894-900. PubMed ID: 3664490
[TBL] [Abstract][Full Text] [Related]
9. Detection of lysosomal cysteine proteinases in microglia: flow cytometric measurement and histochemical localization of cathepsin B and L.
Banati RB; Rothe G; Valet G; Kreutzberg GW
Glia; 1993 Feb; 7(2):183-91. PubMed ID: 8432559
[TBL] [Abstract][Full Text] [Related]
10. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
11. Effect of forphenicinol, a small molecular immunomodifier, in combination with cyclophosphamide on growth of and immunity to syngeneic murine tumors.
Nitta K; Tanaka T; Takeuchi M
Cancer Treat Rep; 1985 Mar; 69(3):285-91. PubMed ID: 3978657
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
13. Oral (1-->3),(1-->4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma.
Cheung NK; Modak S
Clin Cancer Res; 2002 May; 8(5):1217-23. PubMed ID: 12006541
[TBL] [Abstract][Full Text] [Related]
14. Muscle aspartyl protease (cathepsin D) activity: detection using a chromophoric substrate and relation to wasting in DBA/2 mice implanted with leukemic L1210 tumor cells.
Bolger GT; Jaramillo J
Can J Physiol Pharmacol; 1996 Oct; 74(10):1141-8. PubMed ID: 9022834
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
16. The influence of Ukrain on the growth of HA-1 tumor in mice: the role of cysteine proteinases as markers of tumor malignancy.
Svechnikova IG; Korolenko TA; Stashko JuF ; Kaledin VI; Nikolin VP; Nowicky JW
Drugs Exp Clin Res; 1998; 24(5-6):261-9. PubMed ID: 10190085
[TBL] [Abstract][Full Text] [Related]
17. Antitumor efficacy of combination chemotherapy with UFT and cyclophosphamide against human breast cancer xenografts in nude mice.
Haga S; Shimizu T; Imamura H; Watanabe O; Kinoshita J; Fukushima M; Kajiwara T
Anticancer Res; 1999; 19(3A):1791-6. PubMed ID: 10470117
[TBL] [Abstract][Full Text] [Related]
18. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide.
Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS
Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053
[TBL] [Abstract][Full Text] [Related]
19. [Increased anti-tumor activity of chemotherapeutic agents combined with direct current against murine transplanted tumors].
Ito H; Nakayama T; Shigematsu N; Nishiguchi I; Hashimoto S
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1854-9. PubMed ID: 3496048
[TBL] [Abstract][Full Text] [Related]
20. Comparison of antitumor effect of recombinant L-asparaginase with wild type one in vitro and in vivo.
Guo QL; Wu MS; Chen Z
Acta Pharmacol Sin; 2002 Oct; 23(10):946-51. PubMed ID: 12370101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
